- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ixabepilone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 3
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Non-Small Cell Lung Cancer
- Interventions
- MV-NIS, Atezolizumab
- Biological
- Lead sponsor
- Vyriad, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- HIV Infections, Hepatic Insufficiency
- Interventions
- nevirapine
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 5
- States / cities
- Bakersfield, California • San Francisco, California • Albany, New York + 1 more
- Conditions
- Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
- Interventions
- PET Tracer, MRI Tracer, 3T PET/MRI
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Nelfinavir mesylate, Efavirenz
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1989
- U.S. locations
- 23
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Nonmuscle-invasive Bladder Cancer
- Interventions
- T3011
- Biological
- Lead sponsor
- ImmVira Pharma Co. Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
- Conditions
- HCV Infection
- Interventions
- VCH 916, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Dallas, Texas • San Antonio, Texas
- Conditions
- Pregnancy, HIV, AIDS
- Interventions
- Norethindrone acetate
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Human Papilloma Virus Vaccines, Attitude to Health
- Interventions
- Top Concern Tailored Intervention, All Concerns Tailored Intervention
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 908 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Influenza
- Interventions
- Sequestration
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Hepatitis C
- Interventions
- filibuvir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas
- Conditions
- HIV Infections
- Interventions
- Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
- Drug
- Lead sponsor
- Margaret A. Fischl, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- HIV Infections
- Interventions
- Peptide Construction 3, Synthetic
- Drug
- Lead sponsor
- Columbia Research Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Covid19, SARS-CoV Infection
- Interventions
- Zinc Picolinate, Resveratrol, Zinc Picolinate Placebo, Resveratrol Placebo
- Dietary Supplement
- Lead sponsor
- Swedish Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hepatitis C, Chronic
- Interventions
- eltrombopag, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 687 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more
- Conditions
- Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 5 Years to 85 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- HIV Infections
- Interventions
- Aldesleukin
- Drug
- Lead sponsor
- Chiron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 18 more
- Conditions
- Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Biological · Other · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Hepatitis C
- Interventions
- Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
- Conditions
- HIV Infections, Hodgkin's Disease
- Interventions
- Vinblastine sulfate, Dacarbazine, Filgrastim, Bleomycin sulfate, Doxorubicin hydrochloride
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more
- Conditions
- COVID-19
- Interventions
- Navigation Services, Brief Counseling, Critical Dialogue, Referral and Digital Brochure
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 554 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- East Saint Louis, Illinois
- Conditions
- Hepatitis C, Medication Adherence
- Interventions
- enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm)
- Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- HIV Infections
- Interventions
- Placebo, TUTI-16 (0.03mg), TUTI-16 (0.1mg), TUTI-16 (0.6mg)
- Other · Biological
- Lead sponsor
- Thymon, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- San Francisco, California